Shorts

1:08
Using Digital Tools to Shift Azheimer Detection Upstream
5 months ago
by
John Showalter, MD, MSIS (+1 more)

1:28
Pioneering Alzheimer Disease Neuroimaging and Neuropathology
5 months ago
by
Takeshi Iwatsubo, MD, PhD(+1 more)

1:03
Seronegative NMOSD in New Diagnostic Criteria
5 months ago
by
Álvaro Cobo-Calvo, MD, PhD(+1 more)

1:07
The Role of Virtual Reality in MS Rehabilitation
5 months ago
by
Tobias Nef, PhD(+1 more)

0:53
Previewing 2026 MDA Conference
5 months ago
by
Angela Lek, PhD(+1 more)

1:02
Rituximab Shows Promise as Long-Term Treatment for Relapsing MS
5 months ago
by
Louie Pasculli(+1 more)

1:20
Enhancing ALS Care Through Clinical Trial Readiness
5 months ago
by
Brian Lin, PhD(+1 more)

1:03
Key Updates Proposed for Revised NMOSD Diagnostic Criteria
5 months ago
by
Shailee Samir Shah, MD(+1 more)

1:03
Phase 2 Data of Vidofludimus Calcium in Progressive MS
5 months ago
by
Robert Fox, MD(+1 more)

1:22
Strategies for Increasing Diversity in Brain Aging Research
5 months ago
by
Charisse Winston-Gray, PhD, MSc(+1 more)

1:20
Media-Driven Misconceptions of Narcolepsy
6 months ago
by
Julie Flygare, JD(+1 more)

0:30
Barriers to Early Diagnosis and Access to Care in MS
7 months ago
by
Ethel Ciampi, MD, MSc(+1 more)

1:30
Collaboration Within the ALS Community
7 months ago
by
Jinsy A. Andrews, MD, MSc(+1 more)

1:30
Safety Considerations for Kygevvi in Tk2d
7 months ago
by
Fabian Somers, PhD(+1 more)

1:30
Data Backing First Treatment for Tk2d
7 months ago
by
Fabian Somers, PhD(+1 more)

1:30
Training the Next Neuromuscular Specialists
7 months ago
by
John Norbury, MD(+1 more)

1:15
Evolving Landscape of Myasthenia Gravis Treatment
7 months ago
by
Leila Darki, MD(+1 more)

1:05
Aerobic Exercise and Promoting Remyelination in MS
8 months ago
by
Lindsey Wooliscroft, MD, MS(+1 more)

1:12
MDS 2025: Learning From Progress in Other Disease States
8 months ago
by
Lorraine Kalia, MD, PhD(+1 more)

1:16
MDS 2025: Biologically Defining Parkinson Disease
8 months ago
by
Tanya Simuni, MD, FAAN(+1 more)

1:32
MDS 2025: Environmental Exposures and PD
8 months ago
by
Web Ross, MD(+1 more)

0:53
MDS 2025: Novel Therapeutics and Biomarkers for PD
8 months ago
by
Veronica Santini, MD, MA(+1 more)

0:38
MDS 2025: PD and the Gut Microbiome
8 months ago
by
Samia Ben Sassi, MD(+1 more)

1:49
MDS 2025: Parkinson Disease and Brain Organization
8 months ago
by
A. Jon Stoessl, CM, MD(+1 more)

0:53
MDS 2025: Exercise and Diet's Impact on Parkinson Disease
8 months ago
by
Jonas Hannestad, MD, PhD(+1 more)

1:21
Migraine Care Needs of the LGBTQIA+ Patient Population
8 months ago
by
Anna Pace, MD(+1 more)

1:16
Impact of Speech and Physical Therapy in Parkinson Disease
8 months ago
by
Cynthia Fox, PhD, CCC-SLP(+1 more)

1:33
Biomarkers to Guide Remyelination Strategies in MS
9 months ago
by
Ahmed Abdelhak, MD(+1 more)

1:07
Early Identification of Atypical Parkinsonian Syndromes
9 months ago
by
David Shprecher, DO, MSci, FAAN(+1 more)

1:28
Subjective Cognitive Complaints During the Interictal Period in Migraine
9 months ago
by
Laura Sebrow, PhD(+1 more)
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Earlier Pimavanserin Initiation May Alter Psychosis Symptom Trajectory in Parkinson's Disease, Exploratory Analysis Suggests
2
Discontinuing Disease-Modifying Therapy in Older Patients With MS: John Corboy, MD
3
Real-World Survey Data Suggest Deutetrabenazine May Improve Quality of Life Measures in Huntington Disease Chorea
4
Subcutaneous Apomorphine Infusion Titration Reaches Optimization Without Antiemetics in Real-World PD Cohort
5
